Patents by Inventor Jenny L. Gerster

Jenny L. Gerster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11220500
    Abstract: The present invention provides a novel crystalline form of Valbenazine dibesylate, Valbenazine dibesylate Form APO-I, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of hyperkinetic disorders, including tardive dyskinesia.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: January 11, 2022
    Assignee: Apotex Inc.
    Inventors: Mohammed Abdul Raheem, Yajun Zhao, Minh T. N. Nguyen, Mohamed Ibrahim Zaki, Jenny L. Gerster, Stuart P. Green, Allan W. Rey
  • Patent number: 11072620
    Abstract: The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 27, 2021
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Jenny L. Gerster, Annyt Bhattacharyya, Boris Gorin, Allan W. Rey
  • Publication number: 20200207761
    Abstract: The present invention provides a novel crystalline form of Valbenazine dibesylate, Valbenazine dibesylate Form APO-I, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of hyperkinetic disorders, including tardive dyskinesia.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 2, 2020
    Inventors: Mohammed Abdul Raheem, Yajun Zhao, Minh T. N. Nguyen, Mohamed Ibrahim Zaki, Jenny L. Gerster, Stuart P. Green, Allan W. Rey
  • Publication number: 20200095255
    Abstract: The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.
    Type: Application
    Filed: June 15, 2018
    Publication date: March 26, 2020
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Jenny L. Gerster, Annyt Bhattacharyya, Boris Gorin, Allan W. Rey
  • Patent number: 10513500
    Abstract: The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions including these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provided by the present invention include Lesinurad Forms APO-I, a hemi-methanolate, APO-II, a hemi-ethanolate, and APO-III, a co-crystal of Lesinurad and nicotinamide.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: December 24, 2019
    Assignee: Apotex Inc.
    Inventors: Jenny L. Gerster, Katherine A. Rantanen, Allan W. Rey
  • Patent number: 10407396
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: September 10, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Publication number: 20190263760
    Abstract: The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions including these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provided by the present invention include Lesinurad Forms APO-I, a hemi-methanolate, APO-II, a hemi-ethanolate, and APO-III, a co-crystal of Lesinurad and nicotinamide.
    Type: Application
    Filed: November 9, 2017
    Publication date: August 29, 2019
    Inventors: Jenny L. Gerster, Katherine A. Rantanen, Allan W. Rey
  • Publication number: 20190144397
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Publication number: 20170291882
    Abstract: Solid forms of Mirabegron, including forms APO-I, APO-II, and various salt forms, and processes for the preparation thereof, are provided.
    Type: Application
    Filed: October 1, 2015
    Publication date: October 12, 2017
    Inventors: Allan W. Rey, Annyt Bhattacharyya, Jenny L. Gerster, Sammy Chris Duncan, Mohammed Abdul Raheem, Fan Wang, Stuart P. Green